Article thumbnail

Adjusted odds ratios (OR) of clinical parameters included for most accurate designation of subjects discontinuing treatment due to pulmonary adverse effects.

By Kerstin Pohl (148204), David P. Nichols (196771), Jennifer L. Taylor-Cousar (267640), Milene T. Saavedra (344954), Matthew J. Strand (139566), Jerry A. Nick (344955) and Preston E. Bratcher (313359)

Abstract

<p>Adjusted odds ratios (OR) of clinical parameters included for most accurate designation of subjects discontinuing treatment due to pulmonary adverse effects.</p

Topics: Biochemistry, Medicine, Microbiology, Cell Biology, Genetics, Pharmacology, Biotechnology, Immunology, Cancer, Infectious Diseases, Plant Biology, Virology, Chemical Sciences not elsewhere classified, lung function, fibrosis transmembrane conductance regulator, leukocyte surface antigens, CXCR 2 levels, F 508del CFTR mutation Cystic fibrosis, F 508del mutation, discontinuation, potentiates CFTR function, Colorado Adult CF Program, luma, treatment initiation
Year: 2018
DOI identifier: 10.1371/journal.pone.0209026.t004
OAI identifier: oai:figshare.com:article/7457498
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://figshare.com/articles/... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.